April 2018

Important New Products

• Alprolix (eftrenonacog alfa (rhu)) is a long acting, fully recombinant fusion protein consisting ...(more)
• Darzalex (daratumumab (rch)) is an IgG1κ human monoclonal antibody that binds to the CD38 ...(more)
• Fluad (inactivated influenza vaccine (surface antigen), trivalent) contains influenza virus ...(more)
• Gardasil 9 (human papillomavirus 9-valent vaccine) is a noninfectious recombinant 9-valent ...(more)
• Glyxambi (empagliflozin/linagliptin) contains two oral antihyperglycaemic drugs used in the ...(more)
• Olumiant (baricitinib) is a selective and reversible inhibitor of Janus kinases (JAK) 1 and 2, ...(more)
• Qtern (saxagliptin/dapagliflozin) combines saxagliptin and dapagliflozin with distinct and ...(more)

New Contraindications

• Concerta Extended-Release Tablets (methylphenidate hydrochloride) are now ...(more)
• Relenza (zanamivir) is now contraindicated in patients with severe milk protein allergy.
• Viekira Pak (paritaprevir/ritonavir/ombitasvir/dasabuvir) and Viekira Pak-RBV (paritaprevir/ ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. ...(more)